Seribantumab Completed Phase 2 Trials for ER Positive, Her2 Negative Breast Cancer Patients / Triple Negative Breast Cancer Patients Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01421472A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer